Progress of advanced hepatocellular carcinoma adoptive cell therapy based on tumor neoantigens
10.3760/cma.j.cn113884-20211216-00418
- VernacularTitle:基于肿瘤新抗原的晚期肝细胞癌过继免疫细胞治疗相关进展
- Author:
Fangzhou WANG
1
;
Wenwen ZHANG
;
Chonghui LI
;
Shichun LU
Author Information
1. 解放军总医院肝胆胰外科医学部 解放军总医院肝胆外科研究所 全军数字肝胆外科重点实验室，北京 100853
- Keywords:
Carcinoma, hepatocellular;
Adoptive cell therapy;
Tumor neoantigen;
Tumor vaccines
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(9):708-712
- CountryChina
- Language:Chinese
-
Abstract:
Advanced hepatocellular carcinoma has a high degree of malignancy and poor prognosis. Studies showed that there is a close relationship between the progression of hepatocellular carcinoma and the immune status in tumor microenvironment. Adoptive cell therapy showed anti-tumor effects and improve immunosuppression by infusing patients with activated specific immune cells, which become a central issue in tumor therapy and shown promising effects in the treatment of various malignant tumors, indicating great application potential. Adoptive cell therapy based on neoantigen may become a new hot spot in the treatment of hepatocellular carcinoma, and their application, safety and effectiveness evaluation, efficacy prediction and assessment have become urgent issues to be solved. The purpose of this article is to introduce the progress related to adoptive cell therapy for advanced hepatocellular carcinoma and elaborate the problems that need to be solved in the future.
